Modality
Fusion Protein
MOA
IL-17i
Target
PARP
Pathway
Fibrosis
LGS
Development Pipeline
Preclinical
~Jul 2012
→ ~Oct 2013
Phase 1
~Jan 2014
→ ~Apr 2015
Phase 2
~Jul 2015
→ ~Oct 2016
Phase 3
~Jan 2017
→ ~Apr 2018
NDA/BLA
~Jul 2018
→ ~Oct 2019
Approved
Jan 2020
→ Jul 2031
ApprovedCurrent
NCT07395964
1,656 pts·LGS
2020-01→2031-07·Recruiting
1,656 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2031-07-245.3y awayPh3 Readout· LGS
Trial Timeline
2020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q42031Q2Q3Q4
Approved
Recruit…
Catalysts
Ph3 Readout
2031-07-24 · 5.3y away
LGS
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07395964 | Approved | LGS | Recruiting | 1656 | EDSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Miriosocimab | Pfizer | Phase 1 | PARP | |
| SNY-2289 | Sanofi | Phase 2/3 | CD38 | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Fixainavolisib | Takeda | Preclinical | CDK2 | |
| Semainavolisib | Gilead Sciences | Phase 2 | PARP | |
| REG-861 | Regeneron | Phase 2 | PARP | |
| Elrarapivir | Vertex Pharma | NDA/BLA | PRMT5 | |
| Rimaglumide | Biogen | Phase 1/2 | BCL-2 | |
| ARG-3458 | Argenx | Preclinical | RET | |
| Nidaratamab | Krystal Biotech | Preclinical | RET |